Home › Anaplastic Large-Cell Lymphoma
Anaplastic Large-Cell Lymphoma clinical trials recruiting in the U.S.
15 studies for Anaplastic Large-Cell Lymphoma are recruiting participants at sites across the United States.
Cities with the most studies
- Houston, TX4 studies
- Durham, NC4 studies
- Atlanta, GA4 studies
- St. Louis, MO4 studies
- Rochester, MN4 studies
- New York City, NY3 studies
- Seattle, WA3 studies
- Boston, MA3 studies
- Philadelphia, PA3 studies
- Baldwin Park, CA3 studies
- Columbus, OH3 studies
By state
- Arizona3 studies
- California4 studies
- Florida3 studies
- Georgia4 studies
- Illinois3 studies
- Maryland3 studies
- Massachusetts3 studies
- Minnesota4 studies
- Missouri4 studies
- New Jersey3 studies
- New York5 studies
- North Carolina5 studies
- Ohio3 studies
- Pennsylvania4 studies
- Texas5 studies
- Washington3 studies
- Wisconsin3 studies
Recently updated studies
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
RecruitingPhase 1/2
Up to age 25 · All sexes · Updated Sep 25, 2026 · NCT04094610Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06561048Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 14, 2026 · NCT06724237A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Aug 24, 2026 · NCT07055477Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 6, 2026 · NCT07750886Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
RecruitingPhase 1
Ages 12 to 75 · All sexes · Updated Jul 20, 2026 · NCT06176690Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 1, 2026 · NCT06508463Registry of Older Patients With Cancer
RecruitingObservational study
Ages 65 and older · All sexes · Updated Jun 29, 2026 · NCT01137825A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 10, 2026 · NCT03017820Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
RecruitingPhase 2Healthy volunteers welcome
6 Months · All sexes · Updated May 29, 2026 · NCT04195633A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)
RecruitingPhase 1
Ages 18 and older · All sexes · Updated May 26, 2026 · NCT07001384A Registry for People With T-cell Lymphoma
RecruitingObservational study
All ages · All sexes · Updated May 20, 2026 · NCT05978141Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL
RecruitingPhase 2
Ages 1 to 39 · All sexes · Updated May 20, 2026 · NCT07013565Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 3, 2026 · NCT05544968Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Oct 27, 2025 · NCT01137643From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.